IgA nephropathy is a progressive kidney disease characterized by the deposition of immune complexes containing IgA, where a proliferation-inducing ligand (APRIL) drives the production of pathogenic IgA. Jade Biosciences Inc. has developed a novel APRIL-binding therapeutic, JADE-101, for the treatment of IgA nephropathy.